An in-depth analysis of vasodilation in the management of hypertension: Focus on adrenergic blockade

Journal of Cardiovascular Pharmacology

Volumn 53, Issue 5, 2009, Pages 379-387

  Bakris, George ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

blockers; Endothelial dysfunction; Hypertension; Morbidity; Sympathetic nervous system; Vasodilation

Indexed keywords

ACEBUTOLOL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DILEVALOL; LABETALOL; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NEBIVOLOL; NIFEDIPINE; PERINDOPRIL; PROPRANOLOL;

ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; VASCULARIZATION; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; BLOOD PRESSURE; CARBAZOLES; CARDIAC OUTPUT; ETHANOLAMINES; HUMANS; HYPERTENSION; LABETALOL; PROPANOLAMINES; VASCULAR RESISTANCE; VASODILATION;

EID: 67650917880     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31819fd501     Document Type: Review

References (97)

1. Sharma S. Control of arterial blood pressure. Update Anaesthesia. 1992(1):1. Available at: http://www.nda.ox.ac.uk/wfsa/html/u01/u01-008.htm. Accessed October 28, 2008.
2. Mancia G, Grassi G, Giannattasio C, et al. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension. 1999;34(4 pt 2):724-728. (Pubitemid 29501288)
3. Grassi G, Quarti-Trevano F, Dell'Oro R, et al. Essential hypertension and the sympathetic nervous system. Neurol Sci. 2008;29(Suppl 1):S33-S36. (Pubitemid 351836959)
4. Galderisi M, de Divitiis O. Risk factor-induced cardiovascular remodeling and the effects of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol. 2008;51:523-531.
5. Pickering TG. The natural history of hypertension: prehypertension or masked hypertension? J Clin Hypertens. 2007;9:807-810.
6. Sarafidis PA. Proteinuria: natural course, prognostic implications and therapeutic considerations. Minerva Med. 2007;98:693-711.
7. Feihl F, Liaudet L, Levy BI, et al. Hypertension and microvascular remodelling. Cardiovasc Res. 2008;78:274-285.
8. Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep. 2007;9:269-277.
9. Frishman W. A historical perspective on the development of beta-adrenergic blockers. J Clin Hypertens. 2007;9:19-27.
10. Afonso RA, Patarrao RS, Macedo MP, et al. Carvedilol's actions are largely mediated by endogenous nitric oxide. Rev Port Cardiol. 2006;25:911-917.
11. Halcox JPJ, Quyyumi AA. Endothelial function and cardiovascular disease. In: Izzo JL Jr, Sica DA, Black HR, eds. Hypertension Primer: The Essentials of High Blood Pressure. Basic science, Population Science, and Clinical Management. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:204-208.
12. Martinez-Lemus LA, Hill MA, Bolz SS, et al. Acute mechanoadaptation of vascular smooth muscle cells in response to continuous arteriolar vasoconstriction: implications for functional remodeling. FASEB J. 2004;18:708-710.
13. Le Jemtel TH, Ennezar PV. Pathogenesis of chronic heart failure. In: Izzo JL Jr, Sica DA, Black HR, eds. Hypertension Primer: The Essentials of High Blood Pressure. Basic Science, Population Science, and Clinical Management. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:191-194.
14. Klabunde RE. Adrenergic and cholinergic receptors in blood vessels. In: Richard E. Klabunde, ed. Cardiovascular Physiology Concepts. Philadelphia, PA: Lippincott Williams & Wilkins; February 2, 2008. Available at: http://www.cvphysiology.com/Blood%20Pressure/BP010.htm. Accessed October 28, 2008.
15. McCorry LK. Physiology of the autonomic nervous system. Am J Pharm Educ. 2007;71:78.
16. Berecek KH, Carey RM. Adrenergic and dopaminergic receptors and actions. In: Izzo JL Jr, Sica DA, Black HR, eds. Hypertension Primer: The Essentials of High Blood Pressure. Basic Science, Population Science, and Clinical Management. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:39-43.
17. Beevers G, Lip GY, O'Brien E. ABC of hypertension: the pathophysiology of hypertension. BMJ. 2001;322:912-916.
18. Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis. 1998;41(1 Suppl 1):39-52. (Pubitemid 28381714)
19. Takishita S. The sympathetic nervous system in essential hypertension: pathophysiological significance. Intern Med. 2001;40:151-153. (Pubitemid 33665241)
20. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13(8 Suppl B):9-20.
21. Watson T, Goon PK, Lip GY. Endothelial progenitor cells, endothelial dysfunction, inflammation, and oxidative stress in hypertension. Antioxid Redox Signal. 2008;10:1079-1088.
22. Le Brocq M, Leslie SJ, Milliken P, et al. Endothelial dysfunction: from molecular mechanisms to measurement, clinical implications, and therapeutic opportunities. Antioxid Redox Signal. 2008;10:1631-1674. (Pubitemid 351931927)
23. Schulz E, Jansen T, Wenzel P, et al. Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid Redox Signal. 2008;10:1115-1126.
24. Simon G. Pathogenesis of structural vascular changes in hypertension. J Hypertens. 2004;22(1):3-10. (Pubitemid 38293520)
25. Skultetyova D, Filipova S, Riecansky I, et al. The role of angiotensin type 1 receptor in inflammation and endothelial dysfunction. Recent Patents Cardiovasc Drug Discov. 2007;2(1):23-27. (Pubitemid 46813412)
26. Takauchi Y, Yamazaki T, Akiyama T, et al. NG-nitro-L-arginine methyl ester-induced norepinephrine release from cardiac sympathetic nerve endings in anesthetized cats. Neurosci Lett. 2003;353:205-208. (Pubitemid 37510178)
27. Shibasaki M, Low DA, Davis SL, et al. Nitric oxide inhibits cutaneous vasoconstriction to exogenous norepinephrine. J Appl Physiol. 2008;105:1504-1508.
28. Lee MY, Griendling KK. Redox signaling, vascular function, and hypertension. Antioxid Redox Signal. 2008;10:1045-1059.
29. Benetos A, Laurent S, Asmar RG, et al. Large artery stiffness in hypertension. J Hypertens Suppl. 1997;15:S89-S97.
30. Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension. 2002;39:10-15. (Pubitemid 34098081)
31. Epstein M. Aldosterone blockers and potassium-sparing diuretics. In: Izzo JL Jr, Sica DA, Black HR, eds. Hypertension Primer: The Essentials of High Blood Pressure. Basic Science, Population Science, and Clinical Management. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:443-445.
32. Johar S, Cave AC, Narayanapanicker A, et al. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J. 2006;20:1546-1548. (Pubitemid 44943825)
33. Ruilope LM, Izzo JL Jr. Renal risk. In: Izzo JL Jr, Sica DA, Black HR, eds. Hypertension Primer: The Essentials of High Blood Pressure. Basic Science, Population Science, and Clinical Management. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:261-264.
34. Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol. 2007;2:581-590.
35. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252. (Pubitemid 37553153)
36. Kannel WB, Wilson PWF. Cardiovascular risk factors and hypertension. In: Izzo JL Jr, Sica DA, Black HR, eds. Hypertension Primer: The Essentials of High Blood Pressure. Basic Science, Population Science, and Clinical Management. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:244-248.
37. Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens. 2008;21:500-508. (Pubitemid 351589672)
38. Muller-Brunotte R, Kahan T, Lopez B, et al. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J Hypertens. 2007;25:1958-1966. (Pubitemid 47356638)
39. Egan BM, Basile J, Chilton RJ, et al. Cardioprotection: the role of beta-blocker therapy. J Clin Hypertens (Greenwich). 2005;7:409-416.
40. Brixius K, Bundkirchen A, Bolck B, et al. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol. 2001;133:1330-1338. (Pubitemid 32783494)
41. Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens. 2007;25:731-741. (Pubitemid 46398866)
42. Mehvar R, Brocks D. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. J Pharm Pharm Sci. 2001;4:185-201. (Pubitemid 34305610)
43. Siebert CD, Hnsicke A, Nagel T. Stereochemical comparison of nebivolol with other beta-blockers. Chirality. 2008;20:103-109. (Pubitemid 351157095)
44. Leenen FH. Possible significance of the pharmacological differentiation of beta-blockers for therapy of hypertension. Br J Clin Pharmacol. 1979;7(Suppl 2):173S-184S.
45. Messerli FH, Grossman E.β-Blockers in hypertension: is carvedilol different? Am J Cardiol. 2004;93(Suppl):7B-12B.
46. Bakris GL, Fonseca V, Katholi RE, et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension. 2005;46:1309-1315. (Pubitemid 43189728)
47. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(Suppl 1):1-68.
48. Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 2006;99:431-436. (Pubitemid 44304843)
49. Bangalore S, Parkar S, Grossman E, et al. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol. 2007;100:1254-1262. (Pubitemid 47498283)
50. Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004;25:1341-1362.
51. Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int. 2006;70:1905-1913. (Pubitemid 44863377)
52. Awni WM, Skaar DJ, Schwenk MH, et al. Interindividual and intraindividual variability in labetalol pharmacokinetics. J Clin Pharmacol. 1988;28:344-349. (Pubitemid 19013384)
53. Henderson LS, Tenero DM, Baidoo CA, et al. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. Am J Cardiol. 2006;98(Suppl):17L-26L.
54. Prisant LM. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker. J Clin Pharmacol. 2008;48:225-239.
55. Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs. 2007;67:1097-1107. (Pubitemid 46871021)
56. Ignarro LJ. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol. Cardiovasc Ther. 2008;26:115-134.
57. MacCarthy EP, Bloomfield SS. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy. 1983;3:193-219.
58. Szajerski P, Zielonka J, Sikora A, et al. Radical scavenging and NO-releasing properties of selected beta-adrenoreceptor antagonists. Free Radic Res. 2006;40:741-752.
59. Louis WJ, McNeil JJ, Drummer OH. Pharmacology of combined alpha-beta- blockade. I. Drugs. 1984;28(Suppl 2):16-34.
60. Pearce CJ, Wallin JD. Labetalol and other agents that block both alpha-and beta-adrenergic receptors. Cleve Clin J Med. 1994;61(1):59-69; quiz 80-152
61. Kanto JH. Current status of labetalol, the first alpha- and beta-blocking agent. Int J Clin Pharmacol Ther Toxicol. 1985;23:617-628.
62. Kozlovski VI, Lomnicka M, Chlopicki S. Nebivolol and carvedilol induce NO-dependent coronary vasodilatation that is unlikely to be mediated by extracellular ATP in the isolated guinea pig heart. Pharmacol Rep. 2006;58(Suppl):103-110.
63. Kouoh F, Gressier B, Dine T, et al. In vitro and ex vivo antioxidant activities of labetalol on rabbit neutrophil respiratory burst. Adv Ther. 2004;21:178-185.
64. Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 1992;263:92-98.
65. Yue TL, Wang X, Gu JL, et al. Carvedilol, a new vasodilating beta-adrenoceptor blocker, inhibits oxidation of low-density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells. J Pharmacol Exp Ther. 1995;273:1442-1449.
66. Nyberg G, Berglund G. Effects of labetalol and propranolol on the peripheral circulation in hypertensive patients. Acta Med Scand Suppl. 1982;665:93-101. (Pubitemid 13217936)
67. Novo S, Abrignani MG, Sapienza ND, et al. Partial regression of vascular structural alterations in hypertensive patients treated with alpha-beta-blocker, labetalol. Int Angiol. 1992;11:137-141.
68. Opie LH. Role of vasodilation in the antihypertensive and antianginal effects of labetalol: implications for therapy of combined hypertension and angina. Cardiovasc Drugs Ther. 1988;2:369-376.
69. Ohman KP, Weiner L, von Schenck H, et al. Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension. Eur J Clin Pharmacol. 1985;29:149-154. (Pubitemid 16246314)
70. Haenni A, Lithell H. Treatment with a beta-blocker with beta 2-agonism improves glucose and lipid metabolism in essential hypertension. Metabolism. 1994;43:455-461. (Pubitemid 24113166)
71. Lunell NO, Hjemdahl P, Fredholm BB, et al. Circulatory and metabolic effects of a combined alpha- and beta-adrenoceptor blocker (labetalol) in hypertension of pregnancy. Br J Clin Pharmacol. 1981;12:345-348. (Pubitemid 11039903)
72. Fu GS, Huang H, Chen F, et al. Carvedilol ameliorates endothelial dysfunction in streptozotocin-induced diabetic rats. Eur J Pharmacol. 2007;567:223-230. (Pubitemid 46976886)
73. Morgan T, Snowden R, Butcher L. Effect of carvedilol and metoprolol on blood pressure, blood flow, and vascular resistance. J Cardiovasc Pharmacol. 1987;10(Suppl 11):S124-S129. (Pubitemid 18113103)
74. Moser M, Frishman W. Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients. Am J Hypertens. 1998;11(1 pt 2):15S-22S. (Pubitemid 28081683)
75. Weber MA, Bakris GL, Tarka EA, et al. Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. J Clin Hypertens (Greenwich). 2006;8:840-849.
76. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385-1390. (Pubitemid 32455364)
77. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7-13. (Pubitemid 36835815)
78. Bank AJ, Kelly AS, Thelen AM, et al. Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hypertens. 2007;20:777-783. (Pubitemid 46936169)
79. Giugliano D, Marfella R, Acampora R, et al. Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. Diabetes Care. 1998;21:631-636. (Pubitemid 28172947)
80. Gonzalez Maqueda I. Adrenoreceptors, endothelial function, and lipid profile: effects of atenolol, doxazosin, and carvedilol. Coron Artery Dis. 1994;5:909-918.
81. Bjorck S, Mulec H, Johnsen SA, et al. Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. BMJ. 1990;300:904-907. (Pubitemid 20145788)
82. Fassbinder W, Quarder O, Waltz A. Treatment with carvedilol is associated with a significant reduction in microalbuminuria: a multicentre randomised study. Int J Clin Pract. 1999;53:519-522. (Pubitemid 29515823)
83. Marchi F, Ciriello G. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol. Adv Ther. 1995;12:212-221.
84. Ritz E. Reduction of microalbuminuria by beta blockers: beyond renin-angiotensin system blockade. Hypertension. 2005;46:1254-1255. (Pubitemid 43189717)
85. Duka I, Bakris G. Influence of microalbuminuria in achieving blood pressure goals. Curr Opin Nephrol Hypertens. 2008;17:457-463.
86. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227-2236. (Pubitemid 39473160)
87. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med. 1997;126:955-959.
88. Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol. 2003;92:344-348. (Pubitemid 36897730)
89. Pasini AF, Garbin U, Stranieri C, et al. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens. 2008;21:1251-1257.
90. Garbin U, Fratta Pasini A, Stranieri C, et al. Effects of nebivolol on endothelial gene expression during oxidative stress in human umbilical vein endothelial cells. Mediators Inflamm. 2008;2008:367590. (Pubitemid 352000405)
91. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation. 2001;104:511-514. (Pubitemid 32738117)
92. Tarighi B, Kurum T, Demir M, et al. The effects of nebivolol on fibrinolytic parameters in mild and moderate hypertensive patients. Can J Cardiol. 2007;23:651-655. (Pubitemid 47177079)
93. Mahmud A, Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens. 2008;21:663-667. (Pubitemid 351733365)
94. Celik T, Iyisoy A, Kursaklioglu H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens. 2006;24:591-596. (Pubitemid 43261924)
95. Fogari R, Zoppi A, Lazzari P, et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens. 1997;11:753-757. (Pubitemid 27503988)
96. Predel HG, Mainka W, Schillings W, et al. Integrated effects of the vasodilating beta-blocker nebivolol on exercise performance, energy metabolism, cardiovascular and neurohormonal parameters in physically active patients with arterial hypertension. J Hum Hypertens. 2001;15:715-721. (Pubitemid 32975871)
97. Makolkin VI, Akhmedova OO, Buval'tsev VI, et al. [Clinical and metabolic effects of cardioselective beta-adrenoblockers nebivolol and metoprolol in patients with hypertension and ischemic heart disease associated with type 2 diabetes]. Kardiologiia. 2003;43(2):40-43.